Candel Therapeutics Inc’s recent filing unveils that its Director Manning Paul B acquired Company’s shares for reported $7.5 million on Dec 16 ’24. In the deal valued at $6.00 per share,1,250,000 shares were bought. As a result of this transaction, Manning Paul B now holds 1,303,752 shares worth roughly $11.56 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Tyagarajan Seshu sold 20,392 shares, generating $92,898 in total proceeds. Upon selling the shares at $4.56, the Chief Technology Officer now owns 125,657 shares.
Before that, Tak Paul Peter sold 48,847 shares. Candel Therapeutics Inc shares valued at $222,527 were divested by the Chief Executive Officer at a price of $4.56 per share. As a result of the transaction, Tak Paul Peter now holds 294,788 shares, worth roughly $2.61 million.
H.C. Wainwright initiated its Candel Therapeutics Inc [CADL] rating to a Buy in a research note published on December 02, 2022; the price target was $11. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. UBS began covering CADL with “Buy” recommendation on August 23, 2021. Jefferies started covering the stock on August 23, 2021. It rated CADL as “a Buy”.
Price Performance Review of CADL
On Friday, Candel Therapeutics Inc [NASDAQ:CADL] saw its stock fall -3.27% to $8.87. Over the last five days, the stock has lost -10.94%. Candel Therapeutics Inc shares have risen nearly 503.40% since the year began. Nevertheless, the stocks have risen 538.13% over the past one year. While a 52-week high of $14.60 was reached on 12/11/24, a 52-week low of $1.10 was recorded on 01/29/24. SMA at 50 days reached $5.71, while 200 days put it at $6.24.
Levels Of Support And Resistance For CADL Stock
The 24-hour chart illustrates a support level at 8.25, which if violated will result in even more drops to 7.62. On the upside, there is a resistance level at 9.68. A further resistance level may holdings at 10.49. The Relative Strength Index (RSI) on the 14-day chart is 60.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.27, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 56.29%. Stochastics %K at 44.72% indicates the stock is a holding.
How much short interest is there in Candel Therapeutics Inc?
A steep rise in short interest was recorded in Candel Therapeutics Inc stocks on 2024-10-31, growing by 0.19 million shares to a total of 1.78 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 1.59 million shares. There was a rise of 10.79%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 23, 2021 when Credit Suisse began covering the stock and recommended ‘”an Outperform”‘ rating along with a $15 price target.
